Rani Therapeutics (NASDAQ: RANI) has introduced a Analysis Settlement with Chugai Pharmaceutical to guage the feasibility of making use of Rani’s oral supply know-how to Chugai’s antibodies. The settlement, signed on August 13, 2024, covers two molecules with undisclosed targets. Preliminary evaluation reveals the RaniPill® supply system achieved comparable bioavailability to subcutaneous supply for each studied molecules.
Rani has beforehand evaluated 19 various molecules preclinically and accomplished three Section 1 scientific trials with the RaniPill® capsule. The collaboration goals to leverage Rani’s experience in creating oral antibodies, peptides, and enormous proteins with excessive bioavailability alongside Chugai’s technology-driven drug discovery strategy.
Rani Therapeutics (NASDAQ: RANI) ha annunciato un Accordo di Ricerca con Chugai Pharmaceutical per valutare la fattibilità di applicare la tecnologia di somministrazione orale di Rani agli anticorpi di Chugai. L’accordo, firmato il 13 agosto 2024, riguarda due molecole con goal non divulgati. L’analisi iniziale mostra che il sistema di somministrazione RaniPill® ha raggiunto una biodisponibilità comparabile alla somministrazione sottocutanea per entrambe le molecole studiate.
Rani ha precedentemente valutato preclinicamente 19 molecole various e completato tre studi clinici di Fase 1 con la capsula RaniPill®. La collaborazione mira a sfruttare l’esperienza di Rani nello sviluppo di anticorpi orali, peptidi e grandi proteine advert alta biodisponibilità, insieme all’approccio di Chugai basato sulla scoperta di farmaci guidata dalla tecnologia.
Rani Therapeutics (NASDAQ: RANI) ha anunciado un Acuerdo de Investigación con Chugai Pharmaceutical para evaluar la viabilidad de aplicar la tecnología de administración oral de Rani a los anticuerpos de Chugai. El acuerdo, firmado el 13 de agosto de 2024, cubre dos moléculas con objetivos no revelados. El análisis inicial muestra que el sistema de administración RaniPill® logró una biodisponibilidad comparable a la administración subcutánea para ambas moléculas estudiadas.
Rani ha evaluado previamente 19 moléculas diversas en estudios preclínicos y ha completado tres ensayos clínicos de Fase 1 con la cápsula RaniPill®. La colaboración tiene como objetivo aprovechar la experiencia de Rani en el desarrollo de anticuerpos orales, péptidos y proteínas grandes con alta biodisponibilidad, junto con el enfoque de Chugai basado en el descubrimiento de fármacos impulsado por tecnología.
Rani Therapeutics (NASDAQ: RANI)는 Chugai Pharmaceutical과 Rani의 경구 투여 기술을 Chugai의 항체에 적용할 수 있는 가능성을 평가하기 위한 연구 계약을 발표했습니다. 2024년 8월 13일에 체결된 이 계약은 비공개 타겟을 가진 두 분자를 포함합니다. 초기 분석 결과 RaniPill® 투여 시스템이 두 분자 모두에 대해 피하 투여와 유사한 생체이용률을 달성한 것으로 나타났습니다.
Rani는 이전에 19개의 다양한 분자를 비임상적으로 평가했으며 RaniPill® 캡슐로 3건의 1상 임상시험을 완료했습니다. 이번 협력은 고생체이용률을 가진 경구용 항체, 펩타이드 및 대형 단백질 개발에 대한 Rani의 전문성과 Chugai의 기술 중심 신약 개발 방식을 결합하는 것을 목표로 합니다.
Rani Therapeutics (NASDAQ : RANI) a annoncé un accord de recherche avec Chugai Pharmaceutical afin d’évaluer la faisabilité d’appliquer la technologie d’administration orale de Rani aux anticorps de Chugai. L’accord, signé le 13 août 2024, concerne deux molécules avec des cibles non divulguées. L’analyse initiale montre que le système d’administration RaniPill® a atteint une biodisponibilité comparable à celle de l’administration sous-cutanée pour les deux molécules étudiées.
Rani a déjà évalué précliniquement 19 molécules diverses et réalisé trois essais cliniques de section 1 avec la capsule RaniPill®. Cette collaboration vise à tirer parti de l’experience de Rani dans le développement d’anticorps oraux, peptides et grandes protéines à haute biodisponibilité, en complément de l’approche de découverte de médicaments axée sur la technologie de Chugai.
Rani Therapeutics (NASDAQ: RANI) hat eine Forschungsvereinbarung mit Chugai Pharmaceutical bekannt gegeben, um die Machbarkeit der Anwendung von Ranis oraler Verabreichungstechnologie auf Chugais Antikörper zu evaluieren. Die am 13. August 2024 unterzeichnete Vereinbarung umfasst zwei Moleküle mit nicht offengelegten Zielen. Erste Analysen zeigen, dass das RaniPill®-Verabreichungssystem für beide untersuchten Moleküle eine vergleichbare Bioverfügbarkeit wie die subkutane Verabreichung erreichte.
Rani hat zuvor 19 verschiedene Moleküle präklinisch bewertet und drei Section-1-Studien mit der RaniPill®-Kapsel abgeschlossen. Die Zusammenarbeit zielt darauf ab, Ranis Experience in der Entwicklung oraler Antikörper, Peptide und großer Proteine mit hoher Bioverfügbarkeit mit Chugais technologiegetriebener Wirkstoffforschung zu verbinden.
Optimistic
- Analysis settlement with main pharmaceutical firm Chugai validates Rani’s know-how
- RaniPill® demonstrated comparable bioavailability to subcutaneous supply
- Firm has efficiently evaluated 19 molecules preclinically and accomplished 3 Section 1 trials
Insights
Rani Therapeutics’ analysis settlement with Chugai validates their oral biologics supply platform and expands partnership potential.
The analysis settlement between Rani Therapeutics and Chugai Pharmaceutical represents a major validation of Rani’s RaniPill® know-how within the difficult area of oral biologics supply. The information signifies their know-how achieved comparable bioavailability to subcutaneous injection for each molecules studied – a exceptional technical achievement given the historic difficulties in oral supply of enormous molecule medicine.
This collaboration with Chugai, a revered pharmaceutical firm identified for innovation, supplies exterior validation from a longtime trade participant. What makes this significantly noteworthy is the profitable demonstration with antibodies, that are among the many most difficult biologics to ship orally as a consequence of their giant molecular measurement and susceptibility to degradation within the gastrointestinal tract.
The press launch highlights Rani’s increasing observe report, having now evaluated 19 various molecules preclinically and accomplished three Section 1 scientific trials. This rising physique of proof helps the platform’s versatility throughout completely different organic compounds.
Whereas monetary phrases weren’t disclosed, this kind of feasibility evaluation usually precedes extra substantial licensing or growth agreements. This matches with Rani’s enterprise mannequin of doubtless partnering their supply platform with pharmaceutical corporations’ proprietary molecules. For a clinical-stage firm like Rani, these collaborative agreements can present validation, potential milestone funds, and future royalty alternatives with out the total growth price burden of bringing medicine to market independently.
05/19/2025 – 08:00 AM
– Analysis settlement is evaluating feasibility of making use of Rani’s oral supply know-how to Chugai’s antibodies in opposition to undisclosed targets –
SAN JOSE, Calif., Could 19, 2025 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics firm centered on the oral supply of biologics and medicines, immediately introduced the corporate has entered right into a Analysis Settlement on 13th August, 2024, for 2 molecules with undisclosed targets offered by Chugai Pharmaceutical Co., Ltd. (“Chugai”). The total evaluation confirms the RaniPill® supply demonstrated comparable bioavailability to the subcutaneous route of supply for each molecules studied.
“We’re delighted to discover the chance of a collaboration with Chugai, a world-class trade chief with deep analysis and growth capabilities and a popularity for bringing innovation to sufferers,” stated Talat Imran, Chief Govt Officer of Rani Therapeutics. “We consider Chugai’s technology-driven drug discovery strategy for innovation and growth capabilities aligns seamlessly with Rani’s experience in creating oral antibodies, peptides, and enormous proteins with excessive bioavailability. At Rani, up to now, we have now evaluated 19 various molecules preclinically and accomplished three Section 1 scientific trials with the RaniPill® capsule, showcasing its broad applicability throughout a variety of biologics.”
“At Chugai, we’re dedicated to creating modern drug discovery applied sciences primarily based on our technology-driven strategy. We’re honored to have the chance to guage Rani’s know-how, which proposes a pioneering and modern strategy which will doubtlessly unlock important worth throughout a number of packages,” stated Tom Igawa, PhD, Head of Analysis of Chugai Pharmaceutical Co., Ltd.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics firm centered on advancing applied sciences to allow the event of orally administered biologics and medicines. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform know-how, supposed to interchange subcutaneous injection or intravenous infusion of biologics and medicines with oral dosing. Rani has efficiently carried out a number of preclinical and scientific research to guage security, tolerability and bioavailability utilizing RaniPill® capsule know-how. For extra data, go to ranitherapeutics.com.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical firm with world-class drug discovery capabilities, together with proprietary antibody engineering applied sciences. Chugai is dedicated to creating modern pharmaceutical merchandise which will fulfill unmet medical wants. Chugai is listed on the Prime Market of the Tokyo Inventory Trade. Whereas sustaining autonomy and administration independence, Chugai is a crucial member of the Roche Group. Extra data is accessible at
Ahead-Wanting Statements
Statements contained on this press launch relating to issues that aren’t historic information are “forward-looking statements” throughout the which means of the Non-public Securities Litigation Reform Act of 1995. Such forward-looking statements embrace statements relating to, amongst different issues, the alignment of Rani’s and Chugai’s strategy, capabilities and experience, the broad applicability of the RaniPill® capsule know-how, and the potential for the Rani know-how to unlock worth throughout a number of packages. As a result of such statements are topic to dangers and uncertainties, precise outcomes might differ materially from these expressed or implied by such forward-looking statements. Phrases resembling “consider,” “potential,” “anticipate,” “might,” “might” and related expressions are supposed to determine forward-looking statements. These forward-looking statements are primarily based upon Rani’s present expectations and contain assumptions which will by no means materialize or might show to be incorrect. Precise outcomes might differ materially from these anticipated in such forward-looking statements because of numerous dangers and uncertainties, which embrace, with out limitation, dangers and uncertainties related to Rani’s enterprise generally and the opposite dangers described in Rani’s filings with the Securities and Trade Fee, together with Rani’s annual report on Kind 10-Ok for the 12 months ended December 31, 2023, and subsequent filings and experiences by Rani. All forward-looking statements contained on this press launch converse solely as of the date on which they have been made and are primarily based on administration’s assumptions and estimates as of such date. Rani undertakes no obligation to replace such statements to replicate occasions that happen or circumstances that exist after the date on which they have been made, besides as required by regulation.
Investor Contact:
traders@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
FAQ
What’s the objective of the analysis settlement between Rani Therapeutics (RANI) and Chugai?
The settlement goals to guage the feasibility of making use of Rani’s oral supply know-how to Chugai’s antibodies in opposition to undisclosed targets.
What number of molecules has Rani Therapeutics (RANI) evaluated with its RaniPill know-how?
Rani has evaluated 19 various molecules preclinically and accomplished three Section 1 scientific trials with the RaniPill® capsule.
What have been the outcomes of RaniPill’s supply system within the Chugai settlement?
The RaniPill® supply demonstrated comparable bioavailability to the subcutaneous route of supply for each molecules studied.
When was the analysis settlement between Rani Therapeutics and Chugai signed?
The Analysis Settlement was signed on August 13, 2024.
{content material}
Supply: {feed_title}
